94 results about "Drug uptake" patented technology

The invention belongs to the technical field of biology, and discloses a reagent combination or kit for constructing intestinal organs and application of the reagent combination or kit. According to the reagent combination or the kit, intestinal organs can be obtained from cell-derived epithelial cells obtained from a donor in a non-invasive manner, and the obtained intestinal organs can be cryopreserved and recovered and can be amplified in vitro for a long time; transcriptome characteristics are similar to those of real human small intestine tissues, and typical marker genes of various small intestine pedigree cell types are highly expressed; compared with intestinal organs obtained through induction of pluripotent stem cells, the intestinal organs have more intestinal pedigree characteristics, and the intestinal function development is more mature; after being promoted to be mature, the intestinal organ also highly expresses genes related to drug absorption and metabolism, has drug absorption capability similar to that of an immortalized intestinal cell line, but more prominently shows intestinal cell lineage characteristics, is closer to an intestinal environment in a real human body, and can be used for screening intestinal disease drugs; the intestinal barrier function is realized.

The invention discloses a subcutaneous injection site detection and recommendation system based on an intelligent algorithm, and aims to improve the safety of long-term subcutaneous injection and the drug absorption efficiency and reduce the risk of related complications such as subcutaneous hemorrhage, subcutaneous induration and subcutaneous fat hyperplasia at the same time. Comprising a subcutaneous tissue detection module for acquiring subcutaneous vascular distribution, fat layer thickness and induration state of a target part through infrared imaging and ultrasonic technologies and generating subcutaneous tissue characteristic data; the data processing module analyzes the feature data by using an image recognition algorithm, and recognizes a blood vessel dense region, induration and a part where fat hyperplasia has occurred; the injection part recommendation module is used for evaluating an analysis result of the data processing module based on a machine learning algorithm in combination with personalized injection historical data of the patient, and generating an optimal injection part recommendation scheme avoiding a risk area; the intelligent imaging and data analysis technology is utilized, the subcutaneous injection part selection accuracy is improved, and the patient comfort and the treatment effect are improved.

The invention belongs to the technical field of pharmaceutical preparations, and relates to traditional Chinese medicine self-assembled nanoparticles for enhancing anti-inflammatory activity as well as a preparation method and application of the traditional Chinese medicine self-assembled nanoparticles. The traditional Chinese medicine self-assembled nanoparticles are prepared from biphenyl cyclooctene type lignan and an oleanane type pentacyclic triterpenoid compound, wherein the mass ratio of the biphenyl cyclooctene type lignan to the oleanane type pentacyclic triterpenoid compound is 1 to (0.125 to 8). Through an anti-solvent exchange method, the carrier-free nanoparticles based on self-assembly of the traditional Chinese medicine active ingredients are prepared by utilizing spontaneous non-covalent interaction between the biphenyl cyclooctene lignan and the oleanane pentacyclic triterpenoid, so that the cytotoxicity is remarkably reduced, the biocompatibility is enhanced, and the toxic and side effects are reduced; meanwhile, the traditional Chinese medicine self-assembled nano-particles have a remarkable cellular uptake effect, the absorption and utilization efficiency of the medicine is improved, and more efficient anti-inflammatory biological activity is shown.

The invention relates to a healthy diet index evaluation method and system based on a diabetic patient. The method comprises the steps that a multi-modal data set of a patient is obtained, the multi-modal data set comprises diet image data, continuous blood glucose monitoring data and medicine use parameters, and mixed food material component analysis processing is conducted on the diet image data to obtain layered nutrition quantification data; performing synergistic effect analysis according to the drug use parameters and the pharmacokinetic model to generate a nutrition absorption correction coefficient; performing time sequence alignment processing on the layered nutrition quantification data and the continuous blood glucose monitoring data, and establishing a blood glucose response prediction model; and generating a diet health assessment report according to the blood glucose response prediction model and the nutrition absorption correction coefficient. According to the method, through the synergistic effect of the multi-modal data, the blood glucose response prediction model and the drug absorption correction coefficient, the diet effect of the diabetic patient can be accurately evaluated, nutrient absorption is optimized, and the scientificity and individuation degree of diet health management of the diabetic patient are effectively improved.

The invention discloses a perfusion-free parallel double-cell intestine-liver chip system and application thereof in drug uptake evaluation, and belongs to the field of biomedical engineering and organ chips. The chip disclosed by the invention is simple in structure, free of an external pump and a complex pipeline, capable of realizing fluid circulation through swinging, convenient to operate, low in cost and small in pollution risk, and also capable of promoting cell differentiation and optimizing hepatocyte functions. The chip integrates a parallel intestinal cell and a liver cell which are communicated through a shared channel, can continuously simulate intestinal absorption and liver first-pass metabolism, and is closer to an in-vivo physiological state. The device adopts a detachable transparent modular design, can be repeatedly used, supports multi-group parallel operation, can improve experimental flux and result repeatability, and is suitable for in-vitro verification of drug absorption, permeability and metabolism evaluation.

A microneedle array system with heterogeneous needles, designed for the enhanced transdermal delivery of bioactive agents for therapeutic and diagnostic purposes. This system includes a variety of microneedle 140 configurations, such as primary and secondary microneedles that differ in size, shape, and material to optimize delivery and functionality. Secondary needles are specifically designed with additional features such as sensors, specialized coatings, and microelectronics to perform tasks beyond simple delivery, such as in-situ detection and measurement of physiological responses, and stimulation for enhanced drug absorption and therapeutic effect.

The invention discloses a preparation method of drug-loaded membrane protein bionic vesicles based on a microfluidic technology and application of the drug-loaded membrane protein bionic vesicles to targeted melanocyte delivery drugs, and belongs to the technical field of pharmaceutical preparations. The method is easy and convenient to operate, assembly of the phospholipid bilayer and insertion of the membrane protein are accurately controlled through the laminar focusing technology, and the stable and efficient drug-loaded membrane protein bionic vesicle is formed. The drug-loaded membrane protein bionic vesicles can effectively target melanocytes, promote the uptake of the vesicles, significantly improve the accumulation of drugs in the melanocytes, and enhance the treatment effect on melanocyte related diseases (such as hyperpigmentation, melanoma, vitiligo and the like). Meanwhile, the drug-loaded bionic vesicles constructed by the invention have relatively low keratinocyte uptake rate, drug uptake of non-targeted tissues is effectively reduced, and side effects of drugs are reduced, so that the drug-loaded membrane protein bionic vesicle system constructed by the invention has great prospects in the aspect of treating melanocyte related diseases.

The utility model relates to a capsule dosing device for rhesus monkeys, which comprises a thick tube and a thin tube, the thin tube is movably mounted in the thick tube in a penetrating manner, and a claw-shaped clamp is arranged at the bottom of the thick tube; the claw-shaped clamp comprises mounting blocks, the mounting blocks are fixedly mounted on the left inner wall and the right inner wall of the thick pipe correspondingly, first springs are fixedly mounted at the bottoms of the two mounting blocks correspondingly, a movable block is fixedly mounted between the bottoms of the two first springs, and a connecting rod is movably mounted at the bottom of the movable block; and adjusting plates are movably mounted at the bottoms of the connecting rods. The capsule administration device for the rhesus monkey can prevent the rhesus monkey from crushing the capsule to influence the accuracy of the administration amount and the drug absorption, so that the success rate of capsule administration can reach 100%, the test quality is ensured, and effective reference is provided for clinical medication; and moreover, the possibility that the teeth of the rhesus monkey hurt people during capsule administration can be effectively avoided, and the safety of people is guaranteed to the greatest extent.

1. The name of this design product: medication head (special suction for the head). 2. Purpose of this design product: to facilitate drug absorption. 3. The key design point of this design product lies in the combination of shape and pattern. 4. The picture or photo that best illustrates the key points of the design: main view.

The invention relates to the technical field of physiological monitoring, in particular to a hepatocellular carcinoma treatment effect analysis system and method based on metabolism comprehensive analysis, and the method comprises the steps: obtaining the evolution condition of hepatocellular carcinoma, the composition condition of drugs and the composition condition of metabolites; drug absorption and transformation analysis is carried out based on the composition condition of the drug and the marking condition of the composition condition of the metabolite, future drug transformation component prediction is carried out based on the drug absorption and transformation analysis result and the evolution condition of the corresponding hepatocellular carcinoma, and drug treatment effect early warning is carried out based on the future drug transformation component prediction. The first-pass effect is corrected through mass spectrum imaging and enzyme activity, the inhibition effect of the tumor microenvironment on drug transformation is quantified, prediction is dynamically adjusted through the future tumor anomaly score ratio, and the accuracy of the time of drug replacement is improved.

The present application relates to the technical field of artificial intelligence, and particularly relates to an individualized medication prediction method based on artificial intelligence, comprising: acquiring a plurality of standard historical medical data sets; acquiring metabolic capacity scores and drug metabolism rates corresponding to all data groups; training to obtain relationship models corresponding to all standard historical medical data sets; acquiring liver metabolism parameters, gene expression parameters and each drug name in a treatment scheme of a patient to obtain a drug metabolism rate; and determining a corresponding prediction drug amount determination method according to whether the drug types in the treatment scheme have a competitive relationship. The present application integrates drug metabolism enzyme-related gene expression and liver metabolism function, simultaneously incorporates drug absorption competition and metabolism enzyme competition when drugs are used in combination, corrects the final output prediction drug amount when drugs are used in combination, so that the model is more suitable for the actual drug use scene, and the accuracy of the prediction result is increased.

This application discloses a sustained-release formula and medicated pillow for the prevention and treatment of allergic rhinitis, including a pillow base with two symmetrically arranged sustained-release mechanisms and a drive mechanism in the bottom mounting compartment. The sustained-release mechanism consists of multiple sustained-release components, each containing a sustained-release tube and a drug storage tube, connected by a U-shaped connecting pipe and a one-way valve; the drug storage tube is inserted into a pierced tube with a filter screen, which balances air pressure and prevents contamination. The drive mechanism drives a sliding valve to reciprocate via a worm gear system, achieving quantitative drug extraction and precise sustained-release; the atomization design of the sustained-release port improves drug absorption efficiency, and the guide holes in the mounting compartment and the ventilation grooves on the pillow surface form a uniform diffusion channel. This solution solves the problems of cumbersome drug replacement, uncontrollable volatilization, and easy deterioration associated with traditional medicated pillows, offering advantages such as precise controlled release, convenient maintenance, and multiple safety protections. It allows for individualized drug administration based on drug characteristics and patient rhythms, significantly improving the effectiveness of sleep aid therapy and the user experience.

The utility model discloses a kind of venous hot compress sleeve, including the rectangular block of the sleeve main body made of skin-friendly material, sleeve main body is equipped with heating area, the left side of sleeve main body is equipped with first connecting belt, the right side of sleeve main body is equipped with second connecting belt, corresponding position of first connecting belt and second connecting belt is equipped with detachable connecting piece respectively, the position of first connecting belt close to sleeve main body is equipped with infusion leather strip connecting piece, the position of second connecting belt close to sleeve main body is equipped with elastic tightness area.The utility model can realize temperature controllable and heat preservation to a certain extent, improve hot compress operation convenience and security, not only can help patient expand venous vessel, promote drug absorption, also can relieve pain caused by vasospasm, reduce swelling or induration.

The invention discloses a gene therapy nose drop for preventing and / or treating coronavirus as well as preparation and application of the gene therapy nose drop, and belongs to the technical field of biological medicines. The nose drop comprises a reagent A and a reagent B. The reagent A is a nano-gene therapy drug solution connecting a self-assembled composite nano-material carrier and a targeted nucleic acid cleavage system through a click reaction, and the cleavage system comprises endonuclease molecules and an hpDNA oligonucleotide probe set. The hpDNA probe can target a coronavirus N gene conserved sequence and a host cell CtslmRNA at the same time through stem-loop structural design, can cut virus RNA to inhibit replication of the virus RNA, and can block the activation process of virus spike protein; the reagent B is an inhalable preparation of an anti-inflammatory chemical drug, and the drug absorption efficiency is remarkably improved by regulating inflammatory reaction. The nose drop can efficiently prevent and treat coronavirus infection and respiratory tract complications caused by the coronavirus infection through a triple mechanism of'gene editing-host regulation-anti-inflammatory treatment 'in combination with the advantage of nasal local administration, and has the obvious characteristics of high bioavailability and low system toxicity.

Described herein are perfusable 3D tubule-on-chip models comprising at least one tubule consisting of one patent lumen circumscribed by organoid-derived cells, and a multifluidic platform comprising at least one individually addressable chip. The models may further include an unseeded tubule, where the seeded tubule and the unseeded tubule are co-localized on the chip, and wherein the tubule and the unseeded tubule are embedded within a gelatin-fibrin extracellular matrix (ECM). Also, described here are methods of producing the described perfusable 3D tubule-on-chip models, and uses of the same.

Compositions for the treatment of acute manifestations because of oxidative injury by reactive oxygen species (ROS) and chronic development of fibrosis are provided. Compositions of the present invention include perfluorocarbon, hydrogen and oxygen gas, N-acetylcysteine, and glycine to counter robust oxidative responses unleashed following injury from both mechanical and non-mechanical conditions. Methods are also disclosed for delivery to challenging locations (olfactory cleft, spinal canal) and in hostile conditions (post trauma brain, spine, and upper and lower airways), with the invention's products "calming" inflamed tissue by neutralizing ROS in both acute and later complications. Active pharmaceutical ingredient(s) can also be employed to provide both acute and chronic benefit, and such active ingredients themselves can be augmented by the composition, enabling increased drug uptake and oxygenation. The present invention provides broad relief in many conditions for both human and companion subjects.

The EG017 gel composition provided by the invention is moderate in viscosity, high in in-vitro release rate and high in stability, and can be used for remarkably improving the use compliance and the treatment effect of androgen alopecia patients. The gel provided by the invention is free from thick, heavy, sticky and greasy feelings and good in refreshing degree; the medicine can be kept for a long time at a medicine application part, medicine absorption is enhanced, and the medicine utilization degree is improved; and a patient can easily insist on taking the medicine.

The invention discloses an intelligent AI biological signal acquisition and analysis system, and belongs to the technical field of biological signal acquisition and analysis. Comprising an experiment preparation module used for animal category determination and parameter presetting, module state detection and environment setting; the experiment target state maintaining module is used for anesthesia management, respiration management, physiological index monitoring, injection position and medicine absorption judgment, animal welfare evaluation and ethical examination suggestion; the experimental data automatic analysis module is used for carrying out real-time data analysis and experimental report generation; the voice and gesture recognition module is used for receiving a voice instruction and a gesture instruction of a user to intelligently control each module; and the remote control module is used for a user to remotely monitor each module through a mobile terminal. According to the invention, the time and error of manually setting parameters are reduced, the animal can be ensured to be in the optimal experiment state, the experiment operation is standardized, and the experiment efficiency and the result accuracy are integrally improved.

A nano abiraterone acetate composition, a preparation method therefor, and an oral tablet thereof. The composition comprises abiraterone acetate, a suspending aid, a surfactant, and a stabilizer in percentage by weight of 1:(0.1-4):(6-20):(0.01-0.1), and is prepared by wet grinding, drying, and dewatering. The oral bioavailability of the product is improved by adding a cholate absorption-promoting agent, such that the influence of food on drug absorption is reduced.

This invention provides a device for applying ointments for rheumatic and immunological diseases, comprising a box body with an ointment chamber at the top and a buffer chamber inside the box body, the buffer chamber having a flat opening; a control rod rotatably connected to the inner cavity of the buffer chamber, a buffer plate being provided on one side of the control rod, and a first spring connecting the buffer plate and the buffer chamber; a conveyor plate rotatably mounted inside a cylindrical chamber, the conveyor plate having multiple transfer grooves evenly distributed around its circumference; a first tube being provided on the top side of the cylindrical chamber and a second tube being provided on the bottom side; a drive mechanism capable of driving the conveyor plate to rotate. The ointment continuously flowing into the buffer chamber pushes the buffer plate towards the bottom of the buffer chamber, and the first spring also provides an elastic force that pushes the buffer plate upwards. Under the mutual pushing action of the ointment and the buffer plate, the ointment is compressed, reducing gaps and air bubbles, and is discharged from the flat opening, resulting in a uniform and dense ointment without gaps, eliminating the need for secondary coating and repair, and reducing drug waste while ensuring drug absorption.

The invention relates to an efficient, stable and high-biocompatibility nano delivery carrier and application thereof in targeted delivery of drugs, and belongs to the technical field of biological medicines and nano materials. The invention relates to an efficient, stable and high-biocompatibility nano delivery carrier. Mainly comprises a microcrystalline carbon cluster set (the microcrystalline carbon cluster set is composed of a large number of microcrystalline carbon nanosheets), phospholipid bimolecular layers on the surfaces of the microcrystalline carbon nanosheets, oxygen functional groups on the microcrystalline carbon nanosheets and a plurality of surface functional modifications on the oxygen functional groups, and the microcrystalline carbon cluster set comprises, by mass, 91-97 parts of carbon and 3-9 parts of oxygen, the microcrystalline carbon cluster set has a porous structure, the aperture is 2-50nm, and the particle size is 50-200nm. The high-efficiency, stable and high-biocompatibility nano delivery carrier prepared by the invention is granular, controllable in size and highly stable in structure, and can be stored for a long time under conventional conditions without deterioration. According to the present invention, various types of drugs can be loaded, the affinity and the targeting property on various cells can be regulated, the drug absorption efficiency can be substantially improved, the treatment effect can be enhanced, the stability is high after the drug enters the organism, the biocompatibility and the safety are high, and the large-batch production can be achieved;

The invention belongs to the technical field of microneedle patches, and discloses a sildenafil citrate microneedle patch preparation method, which comprises: 1, preparing a raw material solution; step 2, vacuum infusion; step 3, vacuum freeze-drying; step 4, demolding; step 5, detecting; and step 6, packaging. According to the sildenafil citrate microneedle patch, the bioavailability of the sildenafil citrate microneedle patch can be improved, the first-pass effect is effectively avoided, and a better way is provided for drug absorption and drug effect exertion; by developing a low-temperature drying process or a stabilizer formula, the drug degradation can be prevented. Meanwhile, the geometric structure of the microneedle is optimized, so that painless penetration can be ensured, deep tissues are not damaged, and the physical stability and the medicine effectiveness of the microneedle patch in the storage period can be ensured; the sildenafil citrate micro-needle patch takes effect quickly in a unique administration mode, and almost has no whole-body side effect; operation pain is avoided through the non-invasive characteristic, and the treatment comfort is improved.

The invention provides an isoalantolactone derivative TYJ2517, namely 3, 4, 5-trimethoxybenzyl aminomethyl 3-demethyleneisoalantolactone as well as preparation and application thereof, and relates to the field of medicinal compounds, the structure of the isoalantolactone derivative is shown as follows: although many anti-cancer drugs have anti-cancer ability, the drugs generate toxicity to normal cells, and the drugs cannot generate toxicity to the normal cells. Therefore, the development of selective anti-cancer active drugs safe to normal cells is particularly important. According to the invention, TYJ2517 is synthesized, the IC50 value of the TYJ2517 to MCF-7 cells is 3.6 + / -0.8 [mu] M, and the IC50 value of the TYJ2517 to L-02 normal cells exceeds 100 [mu] M. A cell drug uptake capability test result shows that the TYJ2517 uptake capability of L-02 normal cells is low, and the TYJ2517 uptake capability of MCF-7 cancer cells is high. When the administration time is 1 hour, the selective anti-cancer index (SI) of the TYJ2517 to MCF-7 breast cancer cells and L-02 normal cells exceeds 40. Mechanism research shows that the activity of the TYJ2517 for resisting MCF-7 cancer cells is a result of inhibiting the expression quantity of PARP1 protein kinase and ROS, inducing early and late apoptosis of the MCF-7 cells and hindering migration and colony of the MCF-7 cells.

This invention discloses a device and method for evaluating in vitro drug absorption under hypergravity conditions, belonging to the field of medical device technology. The device structure includes: a centrifuge, a centrifuge container, and drug absorption evaluation unit units. Each centrifuge container contains multiple sequentially arranged drug absorption evaluation unit units. Each drug absorption evaluation unit includes a supply chamber, a receiving chamber, an intestinal explant, and a microporous mesh. The supply chamber and receiving chamber are positioned opposite each other, with the intestinal explant sandwiched between them. The supply chamber has at least one supply channel, and the receiving chamber has a receiving cavity paired with the supply channel. Each receiving cavity is topped with a microporous mesh to inhibit deformation of the intestinal explant under hypergravity conditions. This device combines structural simplification, preservation of physiological relevance, and ease of detection. Combined with a spectral correction model, it enables accurate and reliable in vitro hypergravity drug absorption studies.

The application discloses application of GCLC in enhancing cell uptake of BNCT drugs. Boron neutron capture therapy (BNCT) has become a promising method for treating osteosarcoma, and the treatment effect depends to a great extent on 10 Accumulation and distribution of B compounds in tumors. The application provides a gene marker capable of enhancing tumor cell uptake of BNCT drugs and application thereof, and proves that targeting GCLC can overcome the limitation of tumor heterogeneity on BNCT drug uptake by utilizing tumor-specific vulnerability.

The invention discloses a nutrition evaluation and personalized nutrition intervention system for children during hospitalization, and relates to the technical field of medical health information, and the system comprises a terminal which is used for collecting daily multi-omics data, medication data and nutrition intake data of children with metabolic diseases; the monitoring equipment is used for collecting daily growth and development data of the metabolic disease children; the processor is used for outputting daily metabolic capability data and nutrient utilization rate data through a neural network according to the multi-omics data; and according to the metabolic capability data and the medication data, performing linear calculation to obtain drug absorption data. According to the scheme, by constructing the knowledge base containing the quantitative parameters and combining interval matching, function calculation and a priority weighting mechanism, the actual influence degree on the nutrients in a multi-drug scene can be accurately calculated, the problem of nutrient influence evaluation deviation caused by neglecting drug dose difference and multi-drug interaction in the prior art is solved, and the evaluation accuracy is improved. The actual influence coefficient of the medicine on various nutrients can be accurately quantified.

The invention discloses an application device for burn wound repair, and belongs to the technical field of burn application equipment.The application device comprises a body surface application layer, a reagent limiting and releasing layer and a medicine storage layer, the body surface application layer is tightly attached to burn skin, net-shaped small holes are formed in the body surface application layer, the reagent limiting and releasing layer is arranged above the body surface application layer, and the medicine storage layer is arranged above the reagent limiting and releasing layer. The body surface pasting layer is fixedly connected with the reagent limiting and releasing layer, and the medicine storage layer is connected with the reagent limiting and releasing layer. In order to overcome the defects that an existing burn application is inconvenient to change medicine, uneven in medicine absorption, poor in application adaptability and the like, the invention provides the application device for repairing burn wounds, and the problems that secondary trauma is easily caused when a traditional application is replaced, residual medicine affects new medicine effect exertion, and the traditional application is difficult to attach to wounds in different shapes are effectively solved.

The application discloses a Sting agonist liposome-warm sensitive gel, a preparation method and application thereof. The Sting agonist liposome-warm sensitive gel comprises a Sting agonist-loaded liposome and a warm sensitive gel, and the preparation method comprises the following steps: preparing the Sting agonist-loaded liposome, adding the warm sensitive gel into a prepared Sting agonist-loaded liposome solution, and stirring until completely dissolved, and the Sting agonist liposome-warm sensitive gel is obtained. The Sting agonist liposome-warm sensitive gel has the advantages of small liposome particle size, good stability, effectively improved cell entry and release behavior of the Sting agonist, avoided burst release effect, in-vivo continuous and stable stimulation of the Sting agonist, better drug efficacy, increased local drug concentration and reduced side effects; the gel matrix can protect the integrity of the liposome and improve the stability of the liposome. The advantages of the liposome and the gel are combined, the drug uptake into cells is increased, and good sustained and controlled release performance is achieved.

The invention belongs to the technical field of pharmaceutical preparations, and provides a probucol sustained-release capsule for reducing the blood fat level and a preparation method thereof, and the probucol sustained-release capsule is prepared by filling a capsule shell with sustained-release pellets, the sustained-release pellet comprises a blank pellet core, a medicine carrying layer, an isolating layer and a sustained-release layer from inside to outside, wherein the medicine carrying layer comprises probucol and an adhesive in a mass ratio of (200-250): (8-12); the slow-release layer is prepared from eudragit RL PO, a plasticizer, a pore-foaming agent and an anti-sticking agent according to the mass ratio of (250 to 300) to (20 to 25) to (20 to 22) to (10 to 18); the pore-foaming agent is prepared from polyethylene glycol 400 and PVP K25 in a mass ratio of (8-12): (3-5). The probucol sustained-release capsule provided by the invention not only has an excellent sustained-release effect, but also enables drug absorption to be less affected by gastric emptying, reduces stimulation to gastrointestinal tracts, and can improve patient compliance.

The invention discloses a pancreas targeted drug delivery system based on bitter gourd extracellular vesicles and application of the pancreas targeted drug delivery system, and belongs to the field of pharmaceutical preparations. Crude extraction bitter gourd extracellular vesicles are obtained through a differential centrifugation method, then the bitter gourd extracellular vesicles are prepared through a size exclusion chromatography method and a sucrose density gradient method, a drug active substance or a drug carrier loaded with the drug active substance is loaded into the bitter gourd extracellular vesicles, and the pancreas targeted drug delivery system is obtained. Compared with a free drug, the enrichment degree of a drug loading system in pancreas is remarkably increased after the drug is loaded. The bitter gourd extracellular vesicles have the remarkable advantages of rich sources, stable yield, low production cost, high use safety and the like. The drug active ingredients are loaded in the vesicles, so that the drug stability can be improved, the gastrointestinal barrier can be overcome, and the drug absorption efficiency and the pancreas accumulation can be remarkably improved. The invention opens up a new thought for research and treatment of pancreas-related diseases, and has a wide application prospect.